Acadia Pharmaceuticals Inc. was downgraded after a drug setback, but strong sales and a robust pipeline offer investment ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...

Jazz Pharmaceuticals' growth is anchored by Xywav and Epidiolex, both generating robust sales and supporting future oncology ...

UEC Breakthrough Year Transitioning to Uranium Production in Wyoming, Burke Hollow Nearing Start-Up in Texas, and the Launch of U.S. Uranium Refining & Conversion Corp Creates ...

Kingspan shares soared on Tuesday as the insulation manufacturer said it is considering floating its advanced building ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...